RAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.

ABSTRACT:

Introduction

Numerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In contrast, drugs based on monoclonal antibodies, enable rapid passive immunization and therefore can be used for emergency pre- and post-exposure prophylaxis of COVID-19. However rapid elimination of antibody-based drugs from the circulation limits their usage for prolonged pre-exposure prophylaxis.

Methods

In current work we developed a recombinant adeno-associated viral vector (rAAV), expressing a SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibody P2C5 fused with a human IgG1 Fc fragment (P2C5-Fc) using methods of mol

SUBMITTER: Esmagambetov IB 

PROVIDER: S-EPMC10098153 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature